Neurosense Therapeutics LtdNASDAQ:NRSNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.1800
- TODAY'S CHANGE (%)0.0062 (0.5282%)
- Bid / Lots1.1600/ 5
- Ask / Lots1.2500/ 3
- Open / Previous Close1.2200 / 1.1738
- Day Range
- 52 Week Range
- Volume96,731
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRSN |
|---|---|---|
| 09:32 ET | 8548 | 1.22 |
| 09:34 ET | 1500 | 1.22 |
| 09:43 ET | 2000 | 1.1937 |
| 09:48 ET | 100 | 1.215 |
| 10:21 ET | 11284 | 1.24 |
| 10:24 ET | 19719 | 1.27 |
| 10:26 ET | 8310 | 1.28 |
| 10:28 ET | 100 | 1.27 |
| 10:39 ET | 1388 | 1.2572 |
| 10:42 ET | 226 | 1.25 |
| 10:44 ET | 5000 | 1.22 |
| 10:46 ET | 500 | 1.226 |
| 11:00 ET | 996 | 1.24 |
| 11:15 ET | 500 | 1.2201 |
| 11:26 ET | 200 | 1.22 |
| 11:44 ET | 100 | 1.22 |
| 12:18 ET | 5000 | 1.2199 |
| 12:52 ET | 200 | 1.22 |
| 01:06 ET | 1578 | 1.2197 |
| 01:15 ET | 1584 | 1.2361 |
| 01:35 ET | 6076 | 1.15 |
| 02:04 ET | 400 | 1.22 |
| 02:13 ET | 400 | 1.19 |
| 02:29 ET | 200 | 1.22 |
| 02:56 ET | 5000 | 1.1924 |
| 02:58 ET | 9231 | 1.1601 |
| 03:21 ET | 450 | 1.209 |
| 03:50 ET | 2000 | 1.23 |
| 03:59 ET | 951 | 1.18 |
May 7, 2024
May 2, 2024
NeuroSense Announces First Quarter 2024 Business Update, from 9:19AM ET on Thursday May 02, 2024 by Dow Jones
9:19AM ET on Thursday May 02, 2024 by Dow Jones
Apr 22, 2024
Apr 18, 2024
Apr 12, 2024
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024, from 8:30AM ET on Friday Apr 12, 2024 by Dow Jones
8:30AM ET on Friday Apr 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neurosense Therapeutics Ltd | 20.3M | -1.5x | --- |
Aptose Biosciences Inc | 20.1M | -0.2x | --- |
Inhibitor Therapeutics Inc | 20.7M | -6.9x | --- |
Biomx Inc | 19.9M | -0.7x | --- |
Goldenwell Biotech Inc | 19.8M | -163.9x | --- |
NeuroBo Pharmaceuticals Inc | 19.6M | -1.5x | --- |
Company Information
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Contact Information
- Headquarters
- 11 Hamenofim St., Building BHERZLIYA, Israel 4672562
- Phone
- ---
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- Mark Leuchtenberger
- Chief Executive Officer, Director
- Alon Ben-Noon
- Chief Financial Officer
- Or Eisenberg
- Chief Medical Officer
- Ferenc Tracik
- Non-Executive Independent Director
- Cary Claiborne
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.76 |
Book Value | $-0.12 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
